Capricor, Inc. is focused on the discovery and development of Cardiac stem cell therapeutics to support or replace cells that have been damaged or lost due to chronic and acute heart disease. Capricor is developing a complete therapy that includes not only a medication to treat the disease symptoms but a healthcare solution that aims to halt the course of disease and ideally return heart tissue to healthy function.

Capricor is a world leader in the development of human cardiac stem cell technology using cells derived from adult (i.e. non-embryonic) heart tissue.

We use a proprietary process to isolate, purify and expand rare candidate stem cells found in adult human tissue. Capricor is pursuing an autologous stem cell model where the stem cells are isolated from the patient themselves with the tremendous safety benefits and no possibility of cell and tissue rejection.

Worldwide patents licensed exclusively from Hopkins University and the University of Rome protect our research and clinical programs. Our scientific founders, who are also members of our Scientific Advisory Board, are recognized as world leaders in cardiology and cardiac stem cell biology.